{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:49:00Z","timestamp":1789750140645,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020984","name":"Cedars Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P50CA217685"],"award-info":[{"award-number":["P50CA217685"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P50CA217685"],"award-info":[{"award-number":["P50CA217685"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32 CA101642"],"award-info":[{"award-number":["T32 CA101642"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.medj.2024.07.022","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T12:16:32Z","timestamp":1723724192000},"page":"100494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1446-9574","authenticated-orcid":false,"given":"Jeffrey A.","family":"How","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Fellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole D.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Celestino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret B.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin R.","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caddie D.","family":"Laberiano Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio A.","family":"Arrechedera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Maren","family":"Solis Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Schmeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpa","family":"Nick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.07.022_bib1","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.medj.2024.07.022_bib2","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.medj.2024.07.022_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/AOG.0000000000004173","article-title":"Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment","volume":"137","author":"Kurnit","year":"2021","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.medj.2024.07.022_bib4","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040626","article-title":"Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer","volume":"13","author":"Patel","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.medj.2024.07.022_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17517","article-title":"Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016","volume":"3","author":"Knisely","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.medj.2024.07.022_bib7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib8","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","volume":"2011","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.medj.2024.07.022_bib9","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib10","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib12","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib14","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib15","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.19.00508","article-title":"Immunotherapy in Ovarian Cancer: Are We There Yet?","volume":"37","author":"Kandalaft","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib16","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.medj.2024.07.022_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib20","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib21","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib22","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib23","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib24","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib25","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib26","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.medj.2024.07.022_bib28","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.07.022_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejps.2009.08.009","article-title":"Paclitaxel and immune system","volume":"38","author":"Javeed","year":"2009","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.medj.2024.07.022_bib30","article-title":"Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.medj.2024.07.022_bib31","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27025","article-title":"Effects of conventional therapeutic interventions on the number and function of regulatory T\u00a0cells","volume":"2","author":"Roselli","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.medj.2024.07.022_bib32","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2024.07.022_bib33","unstructured":"M. Sharp\u00a0& D. Corp. Keytruda (pembrolizumab) [package insert]. US Food and Drug Administration. Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s066lbl.pdf. Revised 1\/2020. Accessed December 12, 2023."},{"key":"10.1016\/j.medj.2024.07.022_bib34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00685842","article-title":"Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines","volume":"32","author":"Lopes","year":"1993","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.medj.2024.07.022_bib35","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3\u00a0weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.07.022_bib36","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib37","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3\u00a0weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib38","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.07.022_bib39","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib40","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib41","article-title":"Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046\/TRU-D","volume":"11","author":"Park","year":"2023","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.medj.2024.07.022_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050946","article-title":"Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer","volume":"13","author":"How","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.medj.2024.07.022_bib43","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.07.022_bib44","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.medj.2024.07.022_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40364-020-00202-7","article-title":"Role of DNA repair defects in predicting immunotherapy response","volume":"8","author":"Zhang","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.medj.2024.07.022_bib46","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-021-00247-3","article-title":"Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy","volume":"6","author":"Lodewijk","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib48","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-21-2834","article-title":"Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer","volume":"28","author":"Liu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.07.022_bib49","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41588-020-0630-5","article-title":"Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy","volume":"52","author":"Jimenez-Sanchez","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.medj.2024.07.022_bib50","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/annonc\/mdw625","article-title":"Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)","volume":"28","author":"Mesnage","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib51","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/1078-0432.CCR-15-2657","article-title":"Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma","volume":"22","author":"Bohm","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2024.07.022_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081182","article-title":"NF-kappaB Signaling in Ovarian Cancer","volume":"11","author":"Harrington","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.medj.2024.07.022_bib53","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/1878-0261.12093","article-title":"New insights into the role of EMT in tumor immune escape","volume":"11","author":"Terry","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib54","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","article-title":"TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression","volume":"31","author":"Yang","year":"2010","journal-title":"Trends Immunol."},{"key":"10.1016\/j.medj.2024.07.022_bib55","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3389\/fimmu.2019.02293","article-title":"WNT\/beta-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2024.07.022_bib56","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms Controlling PD-L1 Expression in Cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.medj.2024.07.022_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"Gonzalez Martin","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib58","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib59","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41571-023-00805-7","article-title":"Problematic crossovers in cancer drug trials","volume":"20","author":"Gyawali","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib61","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101157","article-title":"Lenvatinib plus pembrolizumab a new effective combination of targeted agents","volume":"8","author":"Perez-Fidalgo","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.medj.2024.07.022_bib63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.07.022_bib64","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2024.04.011","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study","volume":"186","author":"Gonzalez-Martin","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.medj.2024.07.022_bib73","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","article-title":"RNA-SeQC: RNA-seq metrics for quality control and process optimization","volume":"28","author":"DeLuca","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.medj.2024.07.022_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.medj.2024.07.022_bib75","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq--a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.medj.2024.07.022_bib76","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.medj.2024.07.022_bib77","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.medj.2024.07.022_bib79","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.medj.2024.07.022_bib65","doi-asserted-by":"crossref","first-page":"642.e1","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.medj.2024.07.022_bib66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/AOG.0000000000002796","article-title":"Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer","volume":"132","author":"Fleming","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.medj.2024.07.022_bib67","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1038\/s41598-021-83858-x","article-title":"Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues","volume":"11","author":"Parra","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2024.07.022_bib68","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1038\/s41598-021-88156-0","article-title":"Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue","volume":"11","author":"Parra","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2024.07.022_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020255","article-title":"Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies","volume":"12","author":"Parra","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.medj.2024.07.022_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.667067","article-title":"Multiplex Immunofluorescence Tyramide Signal Amplification for Immune Cell Profiling of Paraffin-Embedded Tumor Tissues","volume":"8","author":"Hernandez","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.medj.2024.07.022_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.066","article-title":"Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer","volume":"31","author":"Lee","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.medj.2024.07.022_bib72","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1191\/1740774505cn121oa","article-title":"Monitoring event times in early phase clinical trials: some practical issues","volume":"2","author":"Thall","year":"2005","journal-title":"Clin. Trials"},{"key":"10.1016\/j.medj.2024.07.022_bib78","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2024.07.022_bib80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.medj.2024.07.022_bib81","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav. Brain Res."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:02:49Z","timestamp":1768014169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024003039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666634024003039"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.07.022","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100494"}}